Contact Palatin   Site Map  
 
 
 
07-09-14
Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific...
06-27-14
Palatin Technologies to Join Russell Microcap Index...
06-10-14
Palatin Technologies Announces Notification of Patent Allowance On Next Generation Melanocortin Rec...
 

Palatin Technologies, Inc. (NYSE Amex: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Our programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.

Our primary product in development is bremelanotide for the treatment of female sexual dysfunction. In addition, we have development programs or drug candidates for erectile dysfunction, pulmonary diseases, heart failure, obesity and inflammatory diseases.

Palatin Corporate Presentation - May 2014